NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

Daniel A. Pollyea(University of Colorado Cancer Center), Dale L. Bixby(University of Michigan), Alexander E. Perl(UPMC Hillman Cancer Center), Vijaya Raj Bhatt(Susan Thompson Buffett Foundation), Jessica K. Altman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Marcos de Lima(Cleveland Clinic), Amir T. Fathi(Massachusetts General Hospital), James M. Foran, Ivana Gojo(Sidney Kimmel Comprehensive Cancer Center), Aric C. Hall(University of Wisconsin Carbone Cancer Center), Meagan A. Jacoby(Barnes-Jewish Hospital), Jeffrey E. Lancet(Moffitt Cancer Center), Gabriel N. Mannis(Cancer Institute (WIA)), Guido Marcucci(City Of Hope National Medical Center), Michael G. Martin(St. Jude Children's Research Hospital), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jadee Neff(Cancer Institute (WIA)), Reza Nejati(Fox Chase Cancer Center), Rebecca L. Olin(UCSF Helen Diller Family Comprehensive Cancer Center), Mary‐Elizabeth M. Percival(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Thomas Prébet(Smilow Cancer Hospital), Amanda Przespolewski, Dinesh S. Rao(University of Colorado Cancer Center), Farhad Ravandi‐Kashani(The University of Texas MD Anderson Cancer Center), Paul J. Shami(University of Utah), Richard M. Stone(Dana-Farber Brigham Cancer Center), Stephen A. Strickland(Breast Cancer Research Foundation), Kendra Sweet(Moffitt Cancer Center), Pankit Vachhani(University of Colorado Cancer Center), Matthew J. Wieduwilt(University of California San Diego), Kristina M. Gregory(Pancreatic Cancer Action Network), Ndiya Ogba(Pancreatic Cancer Action Network), Martin S. Tallman(Kettering University)
Journal of the National Comprehensive Cancer Network
January 6, 2021
10.6004/jnccn.2021.0002
Cited by 325Open Access
Full Text

Abstract

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.

Related Papers

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network|New England Journal of Medicine|2013|5.1k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Francesco Lo‐Coco, Giuseppe Avvisati, Marco Vignetti et al.|New England Journal of Medicine|2013|1.6k
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
Woo‐Joo Song, Melanie G. Sullivan, Robert D. Legare et al.|Nature Genetics|1999|1.1k
Adverse Prognostic Significance of <i>KIT</i> Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
Peter Paschka, Guido Marcucci, Amy S. Ruppert et al.|Journal of Clinical Oncology|2006|665
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett, Robert K. Hills, Donald Milligan et al.|Journal of Clinical Oncology|2010|650